Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Research & Development (2018 - 2025)

IGC Pharma has reported Research & Development over the past 8 years, most recently at $1.6 million for Q3 2025.

  • Quarterly Research & Development rose 73.17% to $1.6 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Sep 2025, up 19.41% year-over-year, with the annual reading at $3.7 million for FY2025, 3.82% down from the prior year.
  • Research & Development was $1.6 million for Q3 2025 at IGC Pharma, up from $851000.0 in the prior quarter.
  • Over five years, Research & Development peaked at $1.6 million in Q3 2025 and troughed at $276000.0 in Q3 2021.
  • The 5-year median for Research & Development is $852000.0 (2024), against an average of $843631.6.
  • Year-over-year, Research & Development skyrocketed 304.26% in 2022 and then crashed 56.85% in 2023.
  • A 5-year view of Research & Development shows it stood at $377000.0 in 2021, then skyrocketed by 113.79% to $806000.0 in 2022, then increased by 12.03% to $903000.0 in 2023, then dropped by 5.65% to $852000.0 in 2024, then soared by 86.38% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Research & Development are $1.6 million (Q3 2025), $851000.0 (Q2 2025), and $997000.0 (Q1 2025).